PROBODY Trademark

Trademark Overview

On Friday, July 31, 2015, a trademark application was filed for PROBODY with the United States Patent and Trademark Office. The USPTO has given the PROBODY trademark a serial number of 86983300. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Wednesday, January 24, 2024. This trademark is owned by CytomX Therapeutics, Inc.. The PROBODY trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic [ and diagnostic ] agents and preparations consisting primarily of biochemicals, immunoglobulin and antigen-binding fragments for use in cancer therapies; therapeutic [ and diagnostic ] agents, preparations and substances for medical purposes; immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of dysregulated proteolytic activity for medical purposes; immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of oncology for medical purposes
probody

General Information

Serial Number86983300
Word MarkPROBODY
Filing DateFriday, July 31, 2015
Status701 - SECTION 8 - ACCEPTED
Status DateWednesday, January 24, 2024
Registration Number5355828
Registration DateTuesday, December 12, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 23, 2016

Trademark Statements

Goods and ServicesTherapeutic [ and diagnostic ] agents and preparations consisting primarily of biochemicals, immunoglobulin and antigen-binding fragments for use in cancer therapies; therapeutic [ and diagnostic ] agents, preparations and substances for medical purposes; immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of dysregulated proteolytic activity for medical purposes; immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of oncology for medical purposes
Pseudo MarkPRO BODY

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 6, 2015
Primary Code005
First Use Anywhere DateFriday, June 30, 2017
First Use In Commerce DateFriday, June 30, 2017

Trademark Owner History

Party NameCytomX Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameCytomX Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameCytomX Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Wednesday, January 24, 2024NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Wednesday, January 24, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED
Wednesday, January 24, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, November 15, 2023TEAS SECTION 8 RECEIVED
Monday, December 12, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, October 16, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, October 16, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 12, 2017REGISTERED-PRINCIPAL REGISTER
Saturday, November 4, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, November 3, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, November 3, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 2, 2017STATEMENT OF USE PROCESSING COMPLETE
Thursday, October 19, 2017USE AMENDMENT FILED
Thursday, October 19, 2017SOU EXTENSION 3 GRANTED
Thursday, October 19, 2017SOU EXTENSION 3 FILED
Thursday, November 2, 2017DIVISIONAL PROCESSING COMPLETE
Thursday, October 19, 2017DIVISIONAL REQUEST RECEIVED
Monday, October 30, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 19, 2017TEAS REQUEST TO DIVIDE RECEIVED
Thursday, October 19, 2017SOU TEAS EXTENSION RECEIVED
Thursday, October 19, 2017TEAS STATEMENT OF USE RECEIVED
Saturday, April 15, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 13, 2017SOU EXTENSION 2 GRANTED
Thursday, April 13, 2017SOU EXTENSION 2 FILED
Thursday, April 13, 2017SOU TEAS EXTENSION RECEIVED
Tuesday, October 18, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 14, 2016SOU EXTENSION 1 GRANTED
Friday, October 14, 2016SOU EXTENSION 1 FILED
Friday, October 14, 2016SOU TEAS EXTENSION RECEIVED
Tuesday, April 19, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 23, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 23, 2016PUBLISHED FOR OPPOSITION
Wednesday, February 3, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, January 9, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 8, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 7, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 7, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 12, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 12, 2015NON-FINAL ACTION E-MAILED
Thursday, November 12, 2015NON-FINAL ACTION WRITTEN
Thursday, November 12, 2015ASSIGNED TO EXAMINER
Friday, August 7, 2015NOTICE OF PSEUDO MARK E-MAILED
Thursday, August 6, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 4, 2015NEW APPLICATION ENTERED

Related Keywords

probody therapeutic preparations agents diagnostic substances medical purposes field immunotherapies proteolytic